Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | MicrobiomeTrials← Back to trialsNCT03761108
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2019-01-23Est. Completion: 2033-03-30
Enrollment target: 387 participants Locations- Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Moffitt Cancer Center - McKinley Drive, Tampa, Florida, United States
- Emory University Hospital, Atlanta, Georgia, United States
- Indiana University_Michigan Street, Indianapolis, Indiana, United States
- Norton Cancer Institute, Louisville, Kentucky, United States
- C. S. Mott_University of Michigan, Ann Arbor, Michigan, United States
- Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Columbia University Medical Center, New York, New York, United States
- Ohio State University James Cancer Hospital, Columbus, Ohio, United States
- Oregon Health and Science University (OHSU) Marquam Hill Campus, Portland, Oregon, United States
- University of Texas MD Anderson Clinic, Houston, Texas, United States
- Swedish Cancer Institute, Seattle, Washington, United States
- ZNA Psychiatrisch Ziekenhuis Stuivenberg, Antwerp, Belgium
Other microbiome trials you might be interested in
Relapsed/Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in vario…
Birmingham, United StatesEst. completion Nov 2026
Malignancy, HematologicNeoplasms, HematologicNeoplasms, HematopoieticBlood CancerHematological NeoplasmsHematopoietic Malignancies
Cliniques Universitaires Saint-Luc, Brussels, BelgiumUniversitatsklinikum Essen, Essen, North Rhine-Westphalia, GermanyUniversitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR, Mainz, Rhineland-Palatinate, GermanyUniversitatsklinikum Wurzburg, Würzburg, GermanyJapanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi-ken, JapanNagoya City University Hospital, Nagoya, Aichi-ken, JapanNational Cancer Center Hospital East, Kashiwa-shi, Chiba, JapanGunma University Hospital, Maebashi, Gunma, JapanIbaraki Prefectural Central Hospital, Kasama-shi, Ibaraki, JapanUniversity Hospital Kyoto Prefectural Univ of Medicine, Kyoto, Kyoto, JapanSaitama Medical University International Medical Center, Hidaka, Saitama, JapanTokushima Prefectural Central Hospital, Tokushima, Tokushima, JapanJapanese Red Cross Medical Center, Shibuya-ku, Tokyo, JapanKeio University Hospital, Tokyo, JapanNational Cancer Center Korea, Goyang, South KoreaSeoul National University Cancer Hospital, Seoul, South KoreaThe Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South KoreaYonsei University College of Medicine, Severance Hospital, Seoul, South KoreaHospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, SpainClinica Universidad de Navarra, Pamplona, Navarre, SpainUniversitary Hospital La Princesa, Madrid, Salamanca, SpainHospital Universitario Ramon y Cajal, Madrid, SpainHospital Universitario 12 de Octubre, Madrid, SpainHospital Clinico Universitario de Salamanca, Salamanca, SpainRoyal Marsden Hospital, Sutton, Surrey, United KingdomDysmyelopoietic Syndromes
Hematopoetic Myelodysplasia
Myeloid Leukemia, Acute
Nonlymphoblastic Leukemia, Acute
Leukemia, Lymphocytic, Acute
Background:
Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RA…
Bethesda, United StatesEst. completion Apr 30, 2029
Smoldering Multiple Myeloma
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smold…
Birmingham, United StatesEst. completion Feb 27, 2029